Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pharmacogenomic testing reduced drug-gene interactions in depressed patients 

By Brian Buntz | July 13, 2022

Depressed man

[Image by Holger Langmaier from Pixabay]

A study of 1,944 patients published in JAMA found that pharmacogenomic testing helped to minimize drug-gene interactions in patients with major depressive disorder (MDD) but had little to no effect on symptom remission at 24 weeks.

In the randomized trial, 45% of patients who received pharmacogenomic testing had no predicted drug-gene interactions. Of those who received standard of care, 18% had no such interactions.

Patients in the trial were selected from Department of Veterans Affairs (VA) medical centers from July 2017 to February 2021.

“From a VA policy perspective, I don’t think that we would say the study is robust enough that we recommend testing everybody,” said Dr. David Oslin, director of VA’s VISN 4 Mental Illness, Research, Education, and Clinical Center (MIRECC). “The results were not a slam dunk, and in fact, an important outcome of the study is that only about 15% to 20% of the patients had genes that would significantly interfere with the prescribed medication,” Oslin continued in a VA news release. But Oslin reasoned that the data could encourage providers to obtain genetic information to inform the treatment of patients with MDD.

“Future research should explore if there are subgroups of patients who would benefit more from testing,” Oslin concluded.

In theory, validated biomarkers could help inform treatment response, including the choice of alternative antidepressants if an initial therapy proves ineffective. Patients with drug metabolic abnormalities may be less likely to benefit from some antidepressants.

A companion editorial piece published in JAMA concluded that pharmacogenomic testing for next-step antidepressant selection remains a “work in progress.”

Earlier studies published in the Journal of Psychiatric Research and Clinical Psychopharmacology and Neuroscience indicated that pharmacogenomic study might have advantages in terms of effectiveness and tolerability. The former study concluded that pharmacogenetic-informed medication selection “significantly improves outcomes of patients diagnosed with depression or anxiety” in various settings.

There remains a significant unmet need in treating patients with MDD. The NIH estimates that 21.0 million adult Americans have had at least one major depressive episode. Predicting outcomes for individuals with MDD remains challenging, and fewer than 40% of individuals with MDD reach clinical remission after beginning an initial antidepressant therapy.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: major depressive disorder, MDD, pharmacogenomic testing
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
CNS
The CNS drug development drum beat is getting louder
FDA logo
FDA could approve MDMA and psilocybin in 2 years

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50